MedTrace Logo

ACURATE TA™ Valve Implantation Registry: SAVI 2

NCT02663375 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2018-03-19

No results posted yet for this study

Summary

Post-market registry on ACURATE TA™ Transapical Aortic Bioprosthesis and ACURATE TA™ Delivery System implantation in patients presenting severe symptomatic aortic stenosis to collect continued surveillance data pertaining to safety and performance of the device.

Conditions

  • Aortic Stenosis

Interventions

DEVICE

ACURATE TA™ Transapical Aortic Bioprosthesis

ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.

Sponsors & Collaborators

  • Symetis SA

    lead INDUSTRY

Principal Investigators

  • Thomas Walther, Professor · Kerckhoff Klinik

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-01-31
Completion
2016-01-31

Countries

  • Austria
  • Germany
  • Italy
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02663375 on ClinicalTrials.gov